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Introduction {#sec005}
============

Cervical squamous cell carcinoma (CSCC), accounting for about 75--80% of all cervical cancers, is one of the most common gynecological malignancy and leads to the cancer death in women \[[@pone.0193625.ref001], [@pone.0193625.ref002]\]. Walboomers JM and Castellsague X et al found that CSCC was closely associated with high-risk human papillomavirus (HPV) infection \[[@pone.0193625.ref003], [@pone.0193625.ref004]\]. In addition, lymph node metastasis is one of diffusion routes that influence survival and prognosis of CSCC \[[@pone.0193625.ref005], [@pone.0193625.ref006]\]. Once lymph node metastasis occurs, the overall 5-year survival rate for early stage carcinoma of the uterine cervix is reduced to 53%, which lead to the high recurrence rate and poor prognosis of patients with CSCC \[[@pone.0193625.ref007]--[@pone.0193625.ref010]\]. As there are no valid diagnostic and therapeutic methods for CSCC, it is urgent to understand the pathological mechanism and find potential biological markers for diagnosis, therapy and prognosis of patients with CSCC. \[[@pone.0193625.ref011], [@pone.0193625.ref012]\]. Several genes have been identified as the diagnostic and prognostic biomarkers for CSCC. It has been demonstrated that the kinase family member 20a (KIF20A) protein is one potential biomarker for CSCC \[[@pone.0193625.ref013]\]. Additionally, Liu DQ et al suggested that receptor interacting serine/threonine kinase 4 (RIPK4) might act as a potential diagnostic and independent prognostic biomarker for patients with CSCC \[[@pone.0193625.ref014]\].

MicroRNAs (miRNAs) are small non-coding RNAs that are approximately 22 nt in size. They can modulate growth, proliferation, differentiation and apoptosis of cells by regulating target genes expression at the post-transcriptional level. As microRNAs stably present in almost all body fluids, they constitute a new class of non-invasive biomarkers \[[@pone.0193625.ref015]--[@pone.0193625.ref019]\]. It has been reported that the deregulation of miRNAs leads to the occurrence of a number of diseases, such as cancers in cervical \[[@pone.0193625.ref020]\]. MiR-23b/uPA is involved in the HPV-16 E6-associated cervical cancer development \[[@pone.0193625.ref021]\]. MiR-372 is down-regulated in cervical cancer tissues compared with normal cervical tissues \[[@pone.0193625.ref022]\]. The down-regulation of miR-143 is associated with lymph node metastasis and poor prognosis in cervical cancer \[[@pone.0193625.ref023], [@pone.0193625.ref024]\]. It is reported that 6 serum microRNAs including miR-1246, miR-20a, miR-2392, miR-3147, miR-3162-5p and miR-4484 has been identified in predicting lymph node metastasis of CSCC patients \[[@pone.0193625.ref025]\]. In addition, it is found that serum miR-206 is a powerful tool to predict chemoradiotherapy sensitivity in advanced-stage CSCC patients \[[@pone.0193625.ref026]\]. It is noteworthy that the identification of potential miRNAs that participate in survival prediction is essential for establishing novel prognosis strategies for CSCC. Recently, miRNA expression signatures related to prognosis have been found in number of malignancy \[[@pone.0193625.ref027]\]. Hence, we undertook to identify and validate a miRNA expression signature capable of predicting for survivability in CSCC patients.

Material and methods {#sec006}
====================

TCGA data retrieval and analysis {#sec007}
--------------------------------

The BCGSC\_\_IlluminaHiSeq_miRNASeq data were acquired from Firebrowse (<http://firebrowse.org/?cohort=LIHC&download_dialog=true>, 2016-01-28). Level 3 (Reads-per-kilobase-million; RPKM) miRNA-Seq and Level 1 clinical data were downloaded from the TCGA data portal (<http://tcga-data.nci.nih.gov/tcga>) dataset. At the time of analysis, there were 307 clinical histories. Only those clinical histories with miRNA-seq values and sufficient follow-up data (261 cases) were used for further survival analysis. All these cases were randomly divided into Training cohort (131 cases) and Validation cohort (130 cases). There was no significant difference in gender, race, family history, tumor stage, vascular invasion, follow-up time and follow-up result between two cohorts. Clinical characteristics for two cohorts were shown in [Table 1](#pone.0193625.t001){ref-type="table"}.

10.1371/journal.pone.0193625.t001

###### The clinical characteristics of the patients in the two cohorts.
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  ---------------------------------------------------------------------------------------------------------------------------------------------
  Factor                                                All cohorts\      Training cohorts (n = 131)   Validation cohorts (n = 130)   p-value
                                                        (n = 261)                                                                     
  ------------------------------------------- --------- ----------------- ---------------------------- ------------------------------ ---------
  **Age**                                     Mean±SD   48.77±13.49       48.52±13.12                  49.01±13.91                    0.7741

  Median                                      47        47                47                                                          

  **Race**                                    Asian     15                10                           5                              0.3705

  White                                       185       88                97                                                          

  Black or African American                   24        13                11                                                          

  Native hawaiian or other pacific islander   2         2                 0                                                           

  American indian or Alaska native            8         4                 4                                                           

  **Tumor grade**                             G1        15                7                            8                              0.7578

  G2                                          115       54                61                                                          

  G3                                          106       56                50                                                          

  G4                                          1         0                 1                                                           

  Gx                                          21        10                11                                                          

  **Stage**                                   I         136               68                           68                             0.4456

  II                                          61        34                27                                                          

  III                                         40        21                19                                                          

  IV                                          20        7                 13                                                          

  **Lymphovascular**\                         present   71                35                           36                             0.8577
  **Invasion**\                                                                                                                       

  absent                                      65        34                31                                                          

  **Vital status**                            Alive     201               101                          100                            0.4828

  Dead                                        60        30                30                                                          

  **Survival time**                           Mean±SD   1032.85±1137.81   1054±1093.37                 1011.53±1184.76                0.7637\

  Median                                      607       659               601.5                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------

Identification and survival analysis of miRNA signature {#sec008}
-------------------------------------------------------

In order to identify the survival time related miRNAs in CSCC, the single factor Cox proportional hazard (CoxPH) regression model was fitted to the Training cohort data. The statistical significance was set at p\<0.05. After further adjustment, the multi-factor CoxPH regression model was used for identification of miRNA signature in the survival evaluation model of CSCC. A risk score (RS) was calculated using the coefficients from the model, and high *vs*. low risk patients were then compared in the Training cohort and Validation cohort using the log-rank test. Kaplan-Meier curves were used to plot overall survival with miRNA signature expression using Cutoff Finder (<http://molpath.charite.de/cutoff>). In addition, the receiver operating characteristic (ROC) analyses were performed to assess the 5 years' survival rate of miRNA signature of CSCC by using pROC package in R language. The area under the curve (AUC) under binomial exact confidence interval was calculated and the ROC curve was generated.

Network construction of miRNA signature-targets {#sec009}
-----------------------------------------------

Identifying target genes is an important step in studying the function of miRNA in tissues. In this study, target genes of miRNA signature were obtained by miRWalk (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>). According to the miRNA-target pairs, miRNA signature-targets interaction network was established by Cytoscape software (<http://www.cytoscape.org/>).)

Functional annotation of miRNA signature targets {#sec010}
------------------------------------------------

In order to study the biological function of target genes of miRNA signature, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed by using the online software GeneCodis3 (<http://genecodis.cnb.csic.es/analysis>). The threshold of false discovery rate (FDR) \< 0.05 was set as the criteria of statistical significance.

Results {#sec011}
=======

Generation and validation of miRNA signature {#sec012}
--------------------------------------------

The single factor CoxPH regression model fitted to the Training cohort yielded 47 miRNAs ([Table 2](#pone.0193625.t002){ref-type="table"}). A group of miRNA signatures including hsa-mir-642a and hsa-mir-378c ([Table 3](#pone.0193625.t003){ref-type="table"}) was identified that were most strongly associated with survival after multi-factor CoxPH regression model analysis. The miRNA signature was combined with their coefficients within the penalized model to yield the following equation:

10.1371/journal.pone.0193625.t002

###### The single factor CoxPH regression model fitted to the Training cohort.
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  ------------------------------------------------------------------------------------
  miRNA            Coefficient    HR            95%CI\        95%CI\        p-value
                                                lower         upper         
  ---------------- -------------- ------------- ------------- ------------- ----------
  hsa-mir-361      -0.741962146   0.476178666   0.337831316   0.671181479   2.27E-05

  hsa-mir-150      -0.399833202   0.670431863   0.544302388   0.825788924   1.70E-04

  hsa-mir-642a     -0.933407714   0.393211473   0.241114727   0.64125184    1.84E-04

  hsa-mir-142      -0.459467464   0.631619916   0.493836414   0.807845893   2.53E-04

  hsa-mir-378c     -0.704272826   0.494468008   0.330219908   0.74041148    6.28E-04

  hsa-mir-148b     -0.940559471   0.390409352   0.218272292   0.698299636   1.52E-03

  hsa-mir-502      -0.823303663   0.438979018   0.259043417   0.743900693   2.22E-03

  hsa-mir-532      -0.689571509   0.501791036   0.32109448    0.784174938   2.47E-03

  hsa-mir-548o     -1.431560505   0.238935771   0.093023518   0.613719019   2.94E-03

  hsa-mir-629      -0.582879033   0.558288719   0.378627906   0.823199476   3.26E-03

  hsa-mir-3607     -0.455590425   0.634073485   0.465711706   0.863300575   3.81E-03

  hsa-mir-140      -0.831986343   0.435184003   0.245859481   0.770298201   4.29E-03

  hsa-mir-653      -0.559648681   0.571409776   0.384603247   0.848950534   5.59E-03

  hsa-mir-3940     -0.798489446   0.450008213   0.255437141   0.792787577   5.72E-03

  hsa-mir-204      -0.503949703   0.604139769   0.417830953   0.87352279    7.39E-03

  hsa-mir-500b     -0.689845567   0.501653535   0.302748834   0.831237782   7.42E-03

  hsa-mir-659      -0.984396955   0.373664495   0.177043262   0.788649926   9.80E-03

  hsa-mir-33b      -0.49164916    0.611616908   0.421114439   0.888298305   9.82E-03

  hsa-mir-331      -0.661490245   0.516081673   0.311061687   0.856229823   1.04E-02

  hsa-mir-550a-2   -0.713332169   0.490008682   0.282973877   0.848518284   1.09E-02

  hsa-mir-3074     -0.533161438   0.58674707    0.388980125   0.885063534   1.10E-02

  hsa-mir-155      -0.319675972   0.726384368   0.566546989   0.931315954   1.17E-02

  hsa-mir-34a      -0.601640189   0.547912219   0.34001366    0.882928646   1.35E-02

  hsa-mir-942      -0.501600699   0.605560563   0.406007929   0.903193187   1.39E-02

  hsa-mir-101-1    -0.572617152   0.564047308   0.356914365   0.891388514   1.42E-02

  hsa-mir-1306     -0.582090351   0.558729205   0.349290949   0.893748679   1.52E-02

  hsa-mir-146a     -0.298734498   0.741756321   0.579025164   0.950221983   1.81E-02

  hsa-mir-3130-1   -0.335178726   0.715210248   0.538178207   0.950476427   2.09E-02

  hsa-mir-766      -0.453584546   0.635346636   0.432031166   0.93434312    2.12E-02

  hsa-mir-651      -0.444810245   0.640945887   0.435193351   0.94397497    2.43E-02

  hsa-mir-589      -0.602353886   0.547521315   0.323793065   0.925836971   2.46E-02

  hsa-mir-580      -0.907437169   0.403557148   0.18125611    0.898498661   2.63E-02

  hsa-mir-128-2    -0.488785221   0.613371052   0.397361642   0.946805146   2.73E-02

  hsa-mir-153-2    -0.33037904    0.718651284   0.535409284   0.964607232   2.78E-02

  hsa-mir-550a-1   -0.577582055   0.561253808   0.334287794   0.94231929    2.89E-02

  hsa-mir-186      -0.704267306   0.494470737   0.262595738   0.931093978   2.92E-02

  hsa-mir-16-2     -0.435460059   0.646966956   0.43718272    0.957417167   2.94E-02

  hsa-mir-423      -0.630852633   0.532137889   0.29790113    0.950552733   3.31E-02

  hsa-mir-188      -0.536683133   0.58468436    0.353621916   0.966726849   3.65E-02

  hsa-mir-3199-2   0.733244039    2.081823182   1.043660499   4.152679692   3.74E-02

  hsa-mir-128-1    -0.506262412   0.602744184   0.373877643   0.971709751   3.77E-02

  hsa-mir-34c      -0.247813788   0.780505269   0.617220838   0.986986242   3.85E-02

  hsa-mir-335      0.328925144    1.389473842   1.017173297   1.898041918   3.87E-02

  hsa-mir-660      -0.439107775   0.644611303   0.421343551   0.986187474   4.30E-02

  hsa-mir-145      -0.347777277   0.706256158   0.502311525   0.993004812   4.55E-02

  hsa-mir-1468     -0.518087872   0.595658435   0.358192455   0.990554007   4.59E-02

  hsa-mir-99a      -0.209225673   0.811212146   0.659987923   0.997086648   4.68E-02
  ------------------------------------------------------------------------------------

HR: hazard ratio; CI: confidence interval

10.1371/journal.pone.0193625.t003

###### miRNA signature in CSCC.
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  ------------------------------------------------------------
  miRNA          Coefficient   95%CI\     95%CI\   *p*-value
                               lower      Upper    
  -------------- ------------- ---------- -------- -----------
  hsa-mir-642a   -1.318        0.142266   0.5038   4.40E-05

  hsa-mir-378c   -1.006        0.205868   0.6491   5.93E-04
  ------------------------------------------------------------

Risk Score = -1.318×log~2~ (RPKM of hsa-mir-642a)−1.006×log~2~ (RPKM of hsa-mir-378c).

The RS was calculated for each patient in the Training cohort, in which the patients were dichotomized into either the "low risk" (\< median), or the "high risk" (≥ median) group. A highly significant difference was observed between the high risk and the low risk group (p \< 0.001), that was shown in [Fig 1](#pone.0193625.g001){ref-type="fig"}. When the same miRNA signature equation was applied to the Validation cohort, a similar significant difference was also observed between the high risk and the low risk group (p = 0.007), that was shown in [Fig 2](#pone.0193625.g002){ref-type="fig"}. Additionally, we performed 5 years' survival analysis of miRNA signature by ROC and calculated the AUC to assess the discriminatory ability of miRNA signature ([Fig 3](#pone.0193625.g003){ref-type="fig"}). The AUC of the miRNA signature was 0.7221. Our result suggested that the miRNA signature could be the prognosis model for predicting the survival situation of CSCC.

![Kaplan-Meier curves showing CSCC patients dichotomized based on risk score in the Training cohort.\
High risk is defined as a RS ≥ the median in the training cohort, and low risk is defined as a RS \< the median in the Training cohort.](pone.0193625.g001){#pone.0193625.g001}

![Kaplan-Meier curves showing CSCC patients dichotomized based on risk score in the Validation cohort.\
High risk is defined as a RS ≥ the median in the training cohort, and low risk is defined as a RS \< the median in the Validation cohort.](pone.0193625.g002){#pone.0193625.g002}

![5 years' ROC curves of miRNA signature in CSCC.\
The ROC curves were used to show the diagnostic ability of miRNA signature and miRNA signature with 1-Specificity (the proportion of false positive) and sensitivity (the proportion of true positive) and. The x-axis shows 1-specificity and y-axis shows sensitivity.](pone.0193625.g003){#pone.0193625.g003}

MiRNA signature-targets network {#sec013}
-------------------------------

A total of 345 miRNA signature-target pairs were obtained by miRWalk, followed by the construction of the interaction network ([Fig 4](#pone.0193625.g004){ref-type="fig"}). In the network, 316 genes were targets of has-mir-642a and has-mir-378c. The red rhombus and blue-green ellipse represented the miRNA and target genes, respectively.

![MiRNA signature-targets interaction network.\
The red rhombus and blue-green ellipse represented the miRNA and target genes, respectively.](pone.0193625.g004){#pone.0193625.g004}

Functional annotation of miRNA signature targets {#sec014}
------------------------------------------------

According to the GO enrichment analysis, intracellular signal transduction (FDR = 0.0001536), cell proliferation (FDR = 0.0001913) and blood coagulation (FDR = 0.0001913) were the most significantly enriched biological process; protein binding (FDR = 7.47E-12), nucleotide binding (FDR = 5.97E-09) and metal ion binding (FDR = 5.34E-08) were the most significantly enriched molecular function; nucleus (FDR = 5.68E-17), cytoplasm (FDR = 3.66E-15) and membrane (FDR = 7.10E-09) were the most significantly enriched cellular component. The top 15 GO terms were shown in [Table 4](#pone.0193625.t004){ref-type="table"}. MAPK signaling pathway (FDR = 4.14E-05), VEGF signaling pathway (FDR = 8.89E-05) and endocytosis (FDR = 9.18E-05) were significantly enriched signal pathways that covered most genes. The top 15 KEGG terms were shown in [Table 5](#pone.0193625.t005){ref-type="table"}.

10.1371/journal.pone.0193625.t004

###### The enriched top 15 GO terms of miRNA signature targets.
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  GO Items                 Items Details                                                                               No. of genes   FDR
  ------------------------ ------------------------------------------------------------------------------------------- -------------- -----------
  **Biological process**                                                                                                              
  GO:0035556               intracellular signal transduction                                                           4              0.0001536
  GO:0008283               cell proliferation                                                                          3              0.0001913
  GO:0007596               blood coagulation                                                                           3              0.0001913
  GO:0030168               platelet activation                                                                         3              0.0001913
  GO:0043280               positive regulation of cysteine-type endopeptidase activity involved in apoptotic process   3              0.0001913
  GO:0045087               innate immune response                                                                      3              0.0001913
  GO:0007165               signal transduction                                                                         3              0.0002376
  GO:0051146               nerve growth factor receptor signaling pathway                                              3              0.0002376
  GO:0048011               striated muscle cell differentiation                                                        3              0.0002376
  GO:0045944               positive regulation of transcription from RNA polymerase II promoter                        18             0.0002497
  GO:0006357               regulation of transcription from RNA polymerase II promoter                                 6              0.0003527
  GO:0018105               peptidyl-serine phosphorylation                                                             3              0.000354
  GO:0043066               negative regulation of apoptotic process                                                    3              0.000354
  GO:0007281               germ cell development                                                                       3              0.000354
  GO:0006464               protein modification process                                                                3              0.0007776
  **Molecular function**                                                                                                              
  GO:0005515               protein binding                                                                             89             7.47E-12
  GO:0000166               nucleotide binding                                                                          51             5.97E-09
  GO:0046872               metal ion binding                                                                           59             5.34E-08
  GO:0005524               ATP binding                                                                                 33             5.95E-05
  GO:0046872               metal ion binding                                                                           37             6.92E-05
  GO:0008270               zinc ion binding                                                                            38             0.0001139
  GO:0003700               sequence-specific DNA binding transcription factor activity                                 7              0.0001349
  GO:0003677               DNA binding                                                                                 7              0.0001768
  GO:0031625               ubiquitin protein ligase binding                                                            4              0.0002863
  GO:0008134               transcription factor binding                                                                11             0.0003429
  GO:0005525               GTP binding                                                                                 4              0.0004299
  GO:0019003               GDP binding                                                                                 4              0.0004299
  GO:0003924               GTPase activity                                                                             4              0.0004299
  GO:0003690               double-stranded DNA binding                                                                 6              0.0005831
  GO:0003697               single-stranded DNA binding                                                                 3              0.0009546
  **Cellular component**                                                                                                              
  GO:0005634               nucleus                                                                                     112            5.68E-17
  GO:0005737               cytoplasm                                                                                   106            3.66E-15
  GO:0016020               membrane                                                                                    76             7.10E-09
  GO:0005829               cytosol                                                                                     39             1.04E-07
  GO:0005730               nucleolus                                                                                   38             1.10E-07
  GO:0043231               intracellular membrane-bounded organelle                                                    11             1.23E-07
  GO:0016021               integral to membrane                                                                        53             8.89E-06
  GO:0043231               intracellular membrane-bounded organelle                                                    13             1.73E-05
  GO:0016021               integral to membrane                                                                        68             4.08E-05
  GO:0005622               intracellular                                                                               26             0.0001472
  GO:0005654               nucleoplasm                                                                                 14             0.0001523
  GO:0005625               soluble fraction                                                                            4              0.0001675
  GO:0005886               plasma membrane                                                                             4              0.0001675
  GO:0005624               membrane fraction                                                                           16             0.0002292
  GO:0005625               soluble fraction                                                                            8              0.000391

No.: number; FDR: false discovery rate.

10.1371/journal.pone.0193625.t005

###### The enriched top 15 KEGG terms of MiRNA signature targets.
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  KEGG Items   Items_Details                       No. of genes   FDR
  ------------ ----------------------------------- -------------- ----------
  hsa04010     MAPK signaling pathway              13             4.14E-05
  hsa04660     T cell receptor signaling pathway   4              7.86E-05
  hsa05160     Hepatitis C                         4              7.86E-05
  hsa05211     Renal cell carcinoma                7              8.57E-05
  hsa04370     VEGF signaling pathway              5              8.89E-05
  hsa04144     Endocytosis                         10             9.18E-05
  hsa04062     Chemokine signaling pathway         5              9.22E-05
  hsa04910     Insulin signaling pathway           3              9.85E-05
  hsa05223     Non-small cell lung cancer          3              9.85E-05
  hsa04012     Endometrial cancer                  3              9.85E-05
  hsa04662     B cell receptor signaling pathway   3              9.85E-05
  hsa05215     Prostate cancer                     3              9.85E-05
  hsa05218     Melanoma                            3              9.85E-05
  hsa04530     Tight junction                      3              9.85E-05
  hsa05200     Pathways in cancer                  6              0.000105

No.: number; FDR: false discovery rate

Discussion {#sec015}
==========

CSCC is one of the most common gynecological cancers that affect the health of women \[[@pone.0193625.ref001], [@pone.0193625.ref002]\]. In addition, the 5-year overall survival rate is about 80% \[[@pone.0193625.ref007], [@pone.0193625.ref028]\]. Even so, it is needed to understand the pathological mechanism and find potential survival related genes in the development of CSCC. In this study, we found a miRNA signature including hsa-mir-642a and hsa-mir-378c in CSCC, which could be a valuable tool in guiding treatment decisions for CSCC.

Hsa-mir-642a, a primate-specific miRNA, is a tumor suppressor. It is reported that hsa-mir-642a is differentially expressed in lung cancer cells \[[@pone.0193625.ref029]\]. Interaction of hsa-mir-642a-5p and Linc00974 can increase the expression of keratin 19 and activate Notch and TGF-β signaling pathways, which will increase the proliferation and invasion of hepatocellular carcinoma \[[@pone.0193625.ref030]\]. It is found that hsa-mir-642a is over expressed in the pediatric embryonal central nervous system neoplasm that is regarded as a prognostic parameter of patients \[[@pone.0193625.ref031]\]. In addition, the abnormal expression of hsa-mir-642a in myeloma cell lines significantly decreased protein levels of DEP domain containing MTOR interacting, which caused dedifferentiation of myeloma cells \[[@pone.0193625.ref032]\]. It is noteworthy that hsa-mir-642a is associated with cervical cancer prognosis \[[@pone.0193625.ref033]\]. Herein, we also found that hsa-mir-642a was related to survival time of patients with CSCC. Furthermore, cryptochrome circadian clock 2 (*CRY2*) was one of the target genes of hsa-mir-642a. Cryptochrome 2 is circadian clock gene and the hypermethylation of *CRY2* is involved in DNA recombination and repair in long-term shift-workers \[[@pone.0193625.ref034]\]. It has been demonstrated that the genetic variation of *CRY2* is related to metabolic characteristics of type 2 diabetes \[[@pone.0193625.ref035], [@pone.0193625.ref036]\]. In addition, *CRY2* has been suggested to act as a modulator in the development of cancer \[[@pone.0193625.ref037]\]. The expression level of *CRY2* in ovarian cancer is remarkably lower than those in normal ovary \[[@pone.0193625.ref038]\]. The polymorphism in *CRY2* gene has been frequently found associated with increased risk or recurrence of breast and endometrial cancers \[[@pone.0193625.ref039], [@pone.0193625.ref040]\]. Our result showed that hsa-mir-642a was significantly associated with survival time of CSCC and could be a diagnostic and prognostic marker of CSCC.

It is reported that the expression of hsa-mir-378c may enhance cell survival and tumor growth \[[@pone.0193625.ref041]\]. It has been found that hsa-mir-378c is associated with Stage I and Stage II colon cancer compared with normal controls \[[@pone.0193625.ref042]\]. Additionally, the expression of hsa-mir-378c is significantly down-regulated in osteosarcoma, intrahepatic cholangiocarcinoma and advanced stage gastric cancer \[[@pone.0193625.ref043]--[@pone.0193625.ref045]\]. It is worth mentioning that hsa-mir-378c is the member of protective miRNA signatures and correlated with cervical cancer prognosis \[[@pone.0193625.ref033]\]. In this study, we found that hsa-mir-378c was one of the members of miRNA signatures in the CSCC survival analysis. Moreover, myelin regulatory factor (*MYRF*) was one of the target genes of hsa-mir-378c. *MYRF* is a myelin-associated gene and acts as a key transcription factor for oligodendrocyte differentiation and central nervous system myelination. \[[@pone.0193625.ref046]--[@pone.0193625.ref048]\]. In addition, it is the target gene of hsa-mir-423-5p and involved in the immune response or injury in the retina \[[@pone.0193625.ref049]\]. *MYRF* may be involved in the nervous and immune of CSCC. In a word, hsa-mir-378c played a crucial role in the CSCC and could be a diagnostic and prognostic marker in the development of CSCC.

According to the functional annotation analysis of miRNA signature targets, MAPK signaling pathway (FDR = 4.14E-05), VEGF signaling pathway (FDR = 8.89E-05) and endocytosis (FDR = 9.18E-05) were significantly enriched signal pathways that covered most genes. It has been shown that p38 MAPK is involved in a number of cellular processes, including cell survival and death \[[@pone.0193625.ref050], [@pone.0193625.ref051]\]. It is found that human papillomavirus (HPV) 16 E2 can induce apoptosis by inhibiting p38 MAPK/JNK signal pathway in CSCC, which is important for the in vitro growth and migration of cervical squamous carcinoma cells in response to HPV 16 E2 treatment \[[@pone.0193625.ref052]\]. VEGF has been identified as angiogenesis regulator and may be important to restrict tumor growth, progression and metastasis. Vascular proliferation is a characteristic of cervical cancer and high density of microvessels indicates a worse prognosis of the disease \[[@pone.0193625.ref053]\]. Tjalma W et al found that the expression level of VEGF was high in cervical cancers \[[@pone.0193625.ref054]\]. It is suggested that VEGF could stimulate tumor cell proliferation in the early stages and may be responsible for tumorigenesis of cervical cancer \[[@pone.0193625.ref055]\]. In addition, it has been demonstrated that VEGF could be the predictive biomarker for monitoring the recurrence of cervical cancer \[[@pone.0193625.ref056]\]. The endocytosis process is involved in regulating various biological process including cell cycle and apoptosis in cancer cells \[[@pone.0193625.ref057], [@pone.0193625.ref058]\]. It has been reported that endocytosis is associated with CSCC-specific alternative splicing events \[[@pone.0193625.ref059]\]. This suggested that MAPK, VEGF and endocytosis signal pathways may play an important role in CSCC. Inhibition of these signal pathways might be a useful therapeutic strategy for CSCC.

Conclusions {#sec016}
===========

In summary, we have identified and successfully validated a 2-miRNA signature of hsa-mir-642a and hsa-mir-378c in patients with CSCC. The signature adds to the potential predictive role in the survival time of CSCC patients. Therefore, we can detect the expression of hsa-mir-642a and hsa-mir-378c in the blood to predict the survival time of patients with CSCC, which will improve the clinical outcome for patients with CSCC.
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